Search This Blog

Friday, April 25, 2014

SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman’s Disease (MCD) | Johnson & Johnson

First treatment approved for patients with rare blood disorder



SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman’s Disease (MCD) | Johnson & Johnson

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.